Top life sciences deals of 2025 show a market chasing scale
CURRENT BRIEF VERSION: PharmaShots has published its Top 20 Life Sciences Deals of 2025 report, built with DealForma data, underscoring how 2025 dealmaking skewed toward fewer, larger transactions across biopharma. PharmaShots highlighted three headline deals at the top of its ranking: Jiangsu Hengrui Pharma’s up-to-$12.5 billion collaboration with GSK, Innovent Biologics’ roughly $11.4 billion oncology partnership with Takeda, and BioNTech’s about $11.1 billion BNT327 collaboration with Bristol Myers Squibb. Broader industry analyses point in the same direction: 2025 brought lower overall deal counts, but much higher aggregate values, as companies concentrated on late-stage, strategically aligned assets and platform technologies such as bispecifics, AI-enabled discovery, gene editing, and China-originated innovation. That same capital concentration showed up elsewhere in healthcare financing too, with PharmaShots’ Top 20 Healthcare IPOs of 2025 led by Medline Industries’ $7.2 billion raise and followed by Caris Life Sciences and Lumexa Imaging, reflecting investor appetite for scaled platforms, AI-enabled tools, precision medicine, and revenue-generating healthcare businesses. (linkedin.com)
Why it matters: For veterinary professionals, this isn’t a companion animal headline on its face, but it is a useful read on where capital, science, and commercial attention are moving across the broader life sciences market. Large human-health deals often shape the financing environment, partner appetite, and technology transfer pathways that eventually influence animal health, especially in oncology, immunology, rare disease, biologics manufacturing, and AI-driven R&D. The report also reinforces a market signal that buyers and investors are paying premiums for de-risked assets, scalable platforms, and later-stage programs rather than early, single-product bets. That pattern is also being reinforced by large pools of specialist capital, including Blackstone’s newly closed $6.3 billion BXLS VI fund, now the largest life sciences vehicle of its kind. (linkedin.com)
What to watch: Watch whether this “fewer deals, bigger checks” pattern carries into 2026, including in take-private and acquisition activity such as CVC Capital Partners’ proposed roughly €10.9 billion move for Recordati and Eli Lilly’s roughly $7.8 billion Centessa deal. Also watch whether more platform technologies and China-sourced programs spill over into animal health partnerships and investment strategy. (iqvia.com)